Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Paul John Chaplin MSc, Ph.D. | CEO & President | 2.02M | -- | 1967 |
| Mr. Henrik Juuel M.Sc. | CFO & Executive VP | 1.12M | -- | 1965 |
| Mr. Russell Thirsk M.Sc. | Executive VP & COO | -- | -- | 1968 |
| Mr. Rolf Sass Sørensen | Vice President of Investor Relations & Communications | -- | -- | -- |
| Ms. Anu Helena Kerns M.Sc. | Executive VP and Chief People & Sustainability Officer | -- | -- | 1972 |
| Mr. Jean-Christophe May M.B.A., Pharm.D. | Executive VP & Chief Commercial Officer | -- | -- | 1967 |
Bavarian Nordic A/S
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 1,379
Description
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Corporate Governance
Upcoming Events
March 5, 2025 at 10:59 AM UTC
Bavarian Nordic A/S Earnings Date
Recent Events
Recent Events Information Not Available